Literature DB >> 36192532

Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies.

Soha M El-Masry1, Sally A Helmy2,3, Soha A M Helmy4,5, Eman A Mazyed6.   

Abstract

Community and hospital pharmacists always face the challenge to prepare oral liquid extemporaneous formulations to fit the needs of a specific patient population when commercial forms or the required strength is unavailable. This study was performed to prepare a stable patient-friendly oral liquid extemporaneous formulation of bisoprolol. Eight different extemporaneous formulations were prepared using various suspending agent(s). The in vitro dissolution of all extemporaneous formulations was examined. A comprehensive accelerated stability study was carried out to evaluate the adequate beyond-use date of the most optimized extemporaneous formulation. A validated ultra-performance liquid chromatography method was used for the analysis and quantification of bisoprolol in the accelerated stability and bioavailability studies. A group of eight healthy volunteers was enrolled in a two-way cross-over experimental design to study the bioavailability of the most optimized extemporaneous formulation. The pharmacokinetic parameters of bisoprolol were estimated. Extemporaneous suspension containing 0.5% w/v xanthan gum was easily prepared with a simple, natural, safe, sugar-free excipients. It achieved the best dissolution behavior among other extemporaneous suspensions. It was an easily pourable viscous suspension with no sedimentation. At least 98% of the initial concentration of bisoprolol remained throughout the 6-month study period in the selected suspension regardless of the storage conditions. There was no perceptible change in color, odor, or taste, and no noticeable microbial growth was observed in any sample. The selected formulation was bioequivalent to the commercial tablet in terms of the rate and extent of absorption. This research may be of great help during development of appropriate extemporaneous formulation of bisoprolol fumarate. The simple preparation method could be utilized to draw up a standard operating procedure (SOP) easy to use by different types of pharmacy settings.
© 2022. Controlled Release Society.

Entities:  

Keywords:  Bioavailability; Bisoprolol; Extemporaneous suspension; SOP; Stability

Year:  2022        PMID: 36192532     DOI: 10.1007/s13346-022-01239-x

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   5.671


  33 in total

1.  Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods.

Authors:  N Yuksel; A E Kanik; T Baykara
Journal:  Int J Pharm       Date:  2000-11-19       Impact factor: 5.875

2.  Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System.

Authors:  Elena Ramirez; Olga Laosa; Pedro Guerra; Blanca Duque; Beatriz Mosquera; Alberto M Borobia; Suhua H Lei; Antonio J Carcas; Jesus Frias
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

Review 3.  Drugs and drug administration in extreme environments.

Authors:  Thomas E A H Küpper; Bettina Schraut; Burkhard Rieke; Arnica-Verena Hemmerling; Volker Schöffl; Juergen Steffgen
Journal:  J Travel Med       Date:  2006 Jan-Feb       Impact factor: 8.490

Review 4.  Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.

Authors:  Beverley D Glass; Alison Haywood
Journal:  J Pharm Pharm Sci       Date:  2006       Impact factor: 2.327

5.  Tablet splitting: is it worthwhile? Analysis of drug content and weight uniformity for half tablets of 16 commonly used medications in the outpatient setting.

Authors:  Sally A Helmy
Journal:  J Manag Care Spec Pharm       Date:  2015-01

6.  Role of β-blocker therapy in pediatric heart failure.

Authors:  Akash R Patel; Robert E Shaddy
Journal:  Ped Health       Date:  2010

7.  Off-label drug use in hospitalized children.

Authors:  Samir S Shah; Matthew Hall; Denise M Goodman; Pamela Feuer; Vidya Sharma; Crayton Fargason; Daniel Hyman; Kathy Jenkins; Marjorie L White; Fiona H Levy; James E Levin; David Bertoch; Anthony D Slonim
Journal:  Arch Pediatr Adolesc Med       Date:  2007-03

8.  Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.

Authors:  G Leopold; W Ungethüm; J Pabst; Z Simane; K U Bühring; H Wiemann
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

9.  High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.

Authors:  G Haeusler; H J Schliep; P Schelling; K H Becker; M Klockow; K O Minck; H J Enenkel; E Schulze; R Bergmann; C J Schmitges
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

Review 10.  Oral drug therapy in elderly with dysphagia: between a rock and a hard place!

Authors:  Serena Logrippo; Giovanna Ricci; Matteo Sestili; Marco Cespi; Letizia Ferrara; Giovanni F Palmieri; Roberta Ganzetti; Giulia Bonacucina; Paolo Blasi
Journal:  Clin Interv Aging       Date:  2017-01-31       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.